<DOC>
	<DOCNO>NCT01353898</DOCNO>
	<brief_summary>This two part study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics MK-1972 participant HIV-1 infection . In Part 1 , participant randomize receive MK-1972 ( one 5 different dose level give twice per day ) placebo . Part II begin result Part I know ; participant randomize receive MK-1972 ( one dose level , twice per day ) placebo . The primary hypothesis MK-1972 study dos safe well tolerate HIV-1 infected male ; MK-1972 superior antiretroviral activity compare placebo .</brief_summary>
	<brief_title>Study MK-1972 Human Immunodeficiency Virus ( HIV ) -1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy ( MK-1972-003 )</brief_title>
	<detailed_description />
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Stable baseline health . Appropriate use contraception ; condom protection pregnant partner . Documented HIV1 positive Antiretroviral therapy ( ART ) naïve , define never receive antiretroviral agent ≤30 consecutive day investigational antiretroviral agent , exclude integrase inhibitor , ≤60 consecutive day combination ART exclude integrase inhibitor . No investigational agent license ART within 30 day study drug administration . Diagnosis HIV1infection ≥ 3 month prior screen . Exclusion Criteria History stroke , chronic seizure , major neurological disorder . History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological ( outside HIV1 infection ) , renal , respiratory , genitourinary abnormality disease . History clinically significant neoplastic disease . Use immune therapy agent immunosuppressive therapy within 1 month prior treatment study . Requirement chronic daily prescription medication . Current ( active ) diagnosis acute hepatitis due cause . History chronic Hepatitis C unless document cure and/or participant positive serologic test Hepatitis C virus ( HCV ) negative HCV viral load . Positive Hepatitis B surface antigen . Refusal stop use medication , include prescription nonprescription drug herbal remedy ( St. John 's Wort [ Hypericum perforatum ] ) begin approximately 2 week ( 5 halflives ) prior administration initial dose study drug , throughout study ( include washout interval ) , poststudy visit . Consumption excessive amount alcohol , define great 3 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit [ 25 mL/1 ounce ] ) per day . Consumption excessive amount , define great 6 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , caffeinated beverage per day . Smoker 10 cigarettes/day unwilling restrict smoking ≤10 cigarette per day . Major surgery , donation loss 1 unit blood ( approximately 500 mL ) participation another investigational study within 4 week prior screen . History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food . Current regular user illicit drug history drug ( include alcohol ) abuse within approximately 1 year . Participants positive cannabis test evidence drugdependency may enrol discretion investigator . History hepatic gallbladder disease history clinically significant abnormality liver function test , history Gilbert 's Syndrome , history elevate unconjugated bilirubin .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>